# Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

> **NCT00394446** · PHASE1 · COMPLETED · sponsor: **Myrexis Inc.** · enrollment: 48 (actual)

## Conditions studied

- Refractory Solid Tumors

## Interventions

- **DRUG:** MPC-6827

## Key facts

- **NCT ID:** NCT00394446
- **Lead sponsor:** Myrexis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2007-04
- **Final completion:** 2008-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2008-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00394446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00394446, "Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00394446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*